FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Sixth Consecutive Year
03 mai 2021 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 03, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the sixth consecutive year, FeraMAX® has been named the #1...
BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
14 avr. 2021 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 14, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co....
BioSyent Announces Grant of Restricted Share Units
19 mars 2021 17h33 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 19, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 67,252 Restricted...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2020
17 mars 2021 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 17, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2020. Key...
BioSyent Schedules Q4 and Full Year 2020 Earnings Release for March 17, 2021
11 mars 2021 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 11, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available
16 déc. 2020 09h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the...
BioSyent Announces Renewal of Normal Course Issuer Bid
11 déc. 2020 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020
26 nov. 2020 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key...
BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020
17 nov. 2020 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150
05 nov. 2020 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Therapeutic 150, the first new...